https://pharmadevicenews.com/omabit-raises-2m-to-connect-fragmented-clinical-evidence-but-can-ai-improve-drug-development-decisions/ PharmaDeviceNews en 2026-10-27T12:20:29+00:00 Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions? Bright Ventures, Elena Cassidy, Lenore Champagne Beirne, Michael Snyder, Omabit, Stanford StartX, Stanford University https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Generic-Image.webp https://pharmadevicenews.com/orbis-names-a-new-ceo-after-its-1-4bn-billion-novo-nordisk-deal-but-can-ai-designed-macrocycles-replace-injections/ PharmaDeviceNews en 2026-10-27T12:15:22+00:00 Orbis names a new CEO after its $1.4bn billion Novo Nordisk deal, but can AI-designed macrocycles replace injections? Be Biopharma, bluebird bio, Joanne Smith-Farrell, Lilly Ventures, Mikael Dolsten, Morten Graugaard, NEA, nGen, Novo Holdings, Novo Nordisk, Orbis Medicines https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/stevanato-group-and-aptar-pharma-partner-to-accelerate-prefilled-syringe-system-selection-for-biologics/ PharmaDeviceNews en 2026-10-27T12:09:30+00:00 Stevanato Group and Aptar Pharma partner to accelerate prefilled syringe system selection for biologics Alba, Aptar Pharma, AptarGroup, EZ-fill, Nexa, PremiumCoat, Stevanato Group, United States Pharmacopeia, USP 382 https://pharmadevicenews.com/wp-content/uploads/2026/10/Stevanato-and-Aptar-combine-glass-syringes-and-elastomer-components-for-biologics-scaled-e1793102929677.webp https://pharmadevicenews.com/can-avanzanite-accelerate-nhs-access-to-rare-disease-medicines-in-the-uk/ PharmaDeviceNews en 2026-10-27T12:03:23+00:00 Can Avanzanite accelerate NHS access to rare disease medicines in the UK? Adam Plich, Agios Pharmaceuticals, Amicus Therapeutics, Avanzanite Bioscience, Chiesi, MHRA, MVM Partners, NHS, NICE, PYRUKYND, Sarah O'Connell https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp https://pharmadevicenews.com/enhertu-cut-breast-cancer-recurrence-risk-by-53-against-t-dm1-but-will-lung-toxicity-affect-its-use/ PharmaDeviceNews en 2026-10-27T11:04:05+00:00 Enhertu cut breast cancer recurrence risk by 53% against T-DM1, but will lung toxicity affect its use? AstraZeneca, Daiichi Sankyo, DESTINY-Breast05, Enhertu, European Commission, European Medicines Agency, European Society for Medical Oncology, KADCYLA, KATHERINE, New England Journal of Medicine, trastuzumab deruxtecan, trastuzumab emtansine https://pharmadevicenews.com/wp-content/uploads/2026/06/Ibrance-gains-FDA-approval-across-HER2-status-extending-Pfizers-breast-cancer-franchise-e1782660591861.webp https://pharmadevicenews.com/pfizers-talzenna-and-xtandi-cut-prostate-cancer-progression-risk-by-52-but-who-benefits-most/ PharmaDeviceNews en 2026-10-27T10:46:58+00:00 Pfizer’s TALZENNA and XTANDI cut prostate cancer progression risk by 52%, but who benefits most? Astellas Pharma, enzalutamide, FoundationOne CDx, FoundationOne Liquid CDx, New England Journal of Medicine, Pfizer, TALAPRO-2, TALAPRO-3, talazoparib, Talzenna, United States Food and Drug Administration, Xtandi https://pharmadevicenews.com/wp-content/uploads/2025/12/immunotherapy-research.webp https://pharmadevicenews.com/bayers-lynkuet-cut-poor-sleep-reports-sharply-but-does-that-make-it-a-menopause-sleep-treatment/ PharmaDeviceNews en 2026-10-27T09:41:27+00:00 Bayer’s LYNKUET cut poor sleep reports sharply, but does that make it a menopause sleep treatment? Astellas Pharma, Bayer, elinzanetant, fezolinetant, Lynkuet, OASIS-1, OASIS-2, OASIS-3, OASIS-4, The Menopause Society, United States Food and Drug Administration, Veozah https://pharmadevicenews.com/wp-content/uploads/2026/07/Bonerge-Lifescience-launches-EquoYouth-S-equol-clinical-study-for-menopause-symptoms-e1785145612235.webp https://pharmadevicenews.com/aptar-pharma-buys-pulmotree-after-two-year-partnership-but-can-kolibri-unlock-inhaled-biologics/ PharmaDeviceNews en 2026-10-27T09:33:46+00:00 Aptar Pharma buys Pulmotree after two-year partnership, but can Kolibri unlock inhaled biologics? Aptar Digital Health, Aptar Pharma, AptarGroup, Kolibri, Nanopharm, Noble, Pulmotree https://pharmadevicenews.com/wp-content/uploads/2026/10/Aptar-Pharma-acquires-Pulmotree-to-accelerate-Kolibri-inhaler-development-for-complex-medicines-e1793093548691.webp https://pharmadevicenews.com/mirums-atebrioz-reduced-abnormal-bone-volume-in-young-children-but-will-the-fda-expand-its-approval/ PharmaDeviceNews en 2026-10-27T04:55:26+00:00 Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval? Atebrioz, Incyte, Ipsen, Mirum Pharmaceuticals, palovarotene, Pasatru, PROGRESS, Regeneron Pharmaceuticals, Sohonos, United States Food and Drug Administration, University of Pennsylvania, zilurgisertib https://pharmadevicenews.com/wp-content/uploads/2026/06/Mirum-Pharmaceuticals-and-Incyte-strengthen-the-case-for-targeted-ALK2-inhibition-in-FOP-e1781495975633.webp https://pharmadevicenews.com/aimedbios-991m-boehringer-ingelheim-cancer-deal-reaches-human-trials-but-can-bi-4060107-deliver/ PharmaDeviceNews en 2026-10-27T04:51:41+00:00 AimedBio’s $991m Boehringer Ingelheim cancer deal reaches human trials, but can BI 4060107 deliver? AimedBio, BI 4060107, Boehringer Ingelheim, P-ADC, Samsung Medical Center https://pharmadevicenews.com/wp-content/uploads/2026/07/Bio-Thera-tests-a-dual-action-CD25-ADC-against-advanced-solid-tumors-e1785126922532.webp https://pharmadevicenews.com/serp-01-gene-editing-results-support-phase-2-3-plans-for-inherited-lung-and-liver-disease/ PharmaDeviceNews en 2026-10-26T22:01:08+00:00 SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease Boundless Bio, European Respiratory Society, Hannover Medical School, Renji Hospital, Serapha Bio, SERP-01, YolTech Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/10/Gene-editing-research-lab-e1793051707709.webp https://pharmadevicenews.com/orka-001-shows-strong-psoriasis-skin-clearance-results-as-pivotal-trials-approach-in-2027/ PharmaDeviceNews en 2026-10-26T21:24:08+00:00 ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027 ORKA-001, ORKA-002, Oruka Therapeutics, University of Pennsylvania https://pharmadevicenews.com/wp-content/uploads/2026/10/Psoriasis-treatment-e1793049641354.webp https://pharmadevicenews.com/frontiers-fmc-376-triggered-responses-after-kras-inhibitor-failure-but-can-its-dual-state-mechanism-prevent-resistance/ PharmaDeviceNews en 2026-10-25T13:48:27+00:00 Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance? Adagrasib, European Society for Medical Oncology, FMC-376, Frontier Medicines, Keytruda, KRAS G12C, KRAZATI, LUMAKRAS, Marcelo Negrao, MD Anderson Cancer Center, pembrolizumab, PROSPER, sotorasib https://pharmadevicenews.com/wp-content/uploads/2026/06/Guardant360-CDx-FDA-approval-strengthens-the-liquid-biopsy-case-in-HER2-mutant-lung-cancer-e1781185177103.webp https://pharmadevicenews.com/beone-medicines-reports-new-phase-1-results-across-three-liver-and-lung-cancer-programmes/ PharmaDeviceNews en 2026-10-25T13:45:30+00:00 BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes BeOne Medicines, BG-C477, BGB-58067, BGB-B2033, European Society for Medical Oncology, KANDELA-302, Tevimbra, tislelizumab https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp